Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Analyst Gil Blum of Needham maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), reducing the price target to $28.00.Invest ...

Using this method and as a proof of principle, the researchers identified new targets of E3 ligases, RAD18 and CHIP, which are involved in cancer and neurodegenerative diseases, respectively.

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Frizzled (FZD) proteins are the principal receptors of the Wnt signaling pathway. However, whether Wnt ligands induce FZD endocytosis and degradation remains elusive. The transmembrane E3 ubiquitin ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

One early study revealed the kinetic basis for E3 ligase domains within the Nup358/RanBP2 nucleoporin, including structural characterization of a complex between human Nup358/RanBP2, the SUMO E2 Ubc9, ...

One end latches onto the G12D-mutated site of KRAS, while the other grabs a special type of ‘tagging’ enzyme, E3 ligase. Once everything is bundled together, the enzyme adds protein tags ...

Recent research has focused on the roles of specific proteins, such as α-arrestins and E3 ligases, in regulating these processes. Understanding these mechanisms is essential not only for basic ...

Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Kymera Therapeutics Inc. has patented new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 1 ...